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Abstract
Background The purpose of the present investigation is to
determine whether centrosome amplifications are present in
breast tumor cells, whether there are differences of centrosome
amplification between benign breast lesions and breast
carcinomas, and whether centrosomal analysis can be of value
in the diagnosis and prognosis of breast carcinoma.
Methods Using immunofluorescence analysis with an antibody
against γ-tubulin, we analyzed centrosome abnormalities in fine-
needle aspirations of 100 breast lesions (25 cases with benign
lesions and 75 cases with carcinomas).
Results We found that centrosome amplifications, including
numerical centrosome amplification and structural centrosome
amplification, were present in most breast tumors. Cells with
numerical centrosome amplification were found in 23 of 25
benign lesions, and in all 75 cases of breast carcinomas. Cells
with structural centrosome amplification were found in three of
25 benign les ions , and in 69 of 75 breast carcinomas. The
breast carcinomas showed a mean percentage of cells with
numerical centrosome amplification of 4.86% and a mean
percentage of cells with structural centrosome amplification of
3.98%. These percentages were significantly higher than those
in benign lesions, with a numerical centrosome amplification of
2.77% and a structural centrosome amplification of 0.10%.
Furthermore, the mean percentage of cells with structural
centrosome amplification was significantly associated with
HER2/neu overexpression (P  < 0.05) and with negative
estrogen receptor status (P  < 0.05), and had a borderline
association with negative progesterone receptor status (P  =
0.056) in breast carcinomas.
Conclusion Structural centrosome amplification may bear a
close relationship with breast carcinoma and may be a potential
biomarker for diagnosis and prognosis of breast carcinoma.
Introduction
The centrosome consists of a pair of centrioles surrounded by
electron-dense pericentriolar material, and represents the
microtubule organizing center of interphase and mitotic cells.
Because the centrosome plays an important role in the main-
tenance of cellular polarity and chromosome segregation dur-
ing mitosis, the characteristic loss of cell polarity and abnormal
chromosome number (aneuploidy) commonly seen in human
malignant tumors could result from defects in the centrosome
[1-3]. To date, centrosome amplifications are found in the vast
majority of human malignant tumors, including those of the
pancreas, the prostate, the breast, the lung and the colon
[4,5]. In a xenograft model of pancreatic cancer, centrosome
amplification might cause the tumor to progress to a more
advanced stage [6].
In the present study, we analyzed centrosome aberrances in
fine-needle aspirates (FNAs) of breast tumors, evaluated the
differences of centrosome amplification between benign
breast lesions and breast carcinomas, and studied the rela-
tionships between centrosome amplification and the diagno-
sis, as well as the prognosis, of breast carcinoma.
BSA = bovine serum albumin; ER = estrogen receptor; FNA = fine-needle aspiration; PBS = phosphate-buffered saline; PR = progesterone receptor.Breast Cancer Research    Vol 9 No 4    Guo et al.
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Materials and methods
Patient samples
Breast tumors resected from patients in the Cancer Hospital
of the Chinese Academy of Medical Sciences (CAMS) from
March to September 2006 were aspirated with a 23-gauge
needle attached to a 10 ml syringe, and the samples of aspira-
tions were rinsed into a test tube containing 20 ml CytoLyt
solution (Cytyc Corporation, Marlborough, MA, USA). The use
of human tissue samples and the experimental procedures for
this study were reviewed and approved by the ethics commit-
tee of the Cancer Institute/Hospital, CAMS.
Liquid-based preparation
The tubes containing the patient samples were concentrated
by centrifugation for 10 minutes. The supernates were poured
off and the cell pellets were vortexed to become resuspended.
Specimens were added to a PreservCyt solution vial (Cytyc
Corporation) and were allowed to stand in the vial for 15 min-
utes. Vials were then loaded into the ThinPrep 2000 proces-
sor (Cytyc Corporation). After the machine was run using
sequence 2, the monolayer slides were made. For each case
we made two slides, one for cytology diagnosis and another
for centrosome labeling.
Centrosome labeling
The ThinPrep slides were immunostained with an antibody
against γ-tubulin, using the following steps. The slides were
fixed in methanol at -20°C for 30 minutes and in acetone at -
20°C for 6 minutes, were permeabilized in buffer (0.1 M piper-
azine-N, N'-bis-2-ethanesulfonic acid buffer (pH 6.9), 1 mM
ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic
acid, 4 M glycerol, 0.5% Triton X-100, and 1 mM guanosine
triphosphate) for 5 minutes [7], and were immersed in 3%
hydrogen peroxide in PBS for 10 minutes to block endog-
enous peroxidase. The slide was then heated in antigen
retrieval solution in a microwaveable pressure cooker for 30
minutes. Blocking solution (10% normal goat serum, 2% BSA
in PBS) was applied to the slides for 30 minutes and the slides
were incubated with mouse anti-γ-tubulin monoclonal antibody
(diluted 1:200 in PBS; Sigma, St Louis, MO, USA) overnight
at 32°C. The antibody–antigen complexes were detected by a
rhodamine-conjugated antibody after incubation for 30 min-
utes at 37°C. Between the incubations, the slides were
washed extensively with PBS containing 0.1% Tween 20. The
slides were finally counterstained with 4',6-diamidino-2-phe-
nylindole (Vector, Burlingame, CA, USA) and examined under
a fluorescence microscope (Olympus BX-51; Olympus,
Tokyo, Japan). The centrosome images were obtained with the
aid of the image analysis system CytoVision®2.7 (Applied
Imaging, Newcastle, UK).
Calculation of centrosome amplification
Centrosome images from cells of normal mammary tissues
were used as controls. A normal centrosome was detected as
one or two regular rounded spots of uniform size and shape
[4,8]. If there were any centrosomal changes in number and/
or in shape, the centrosome was considered aberrant. The cell
was considered a cell with numerical centrosome amplifica-
tion if it had three or more centrosomes. The cell was consid-
ered a cell with structural centrosome amplification if the
diameter of its centrosome was greater than twice the diame-
ter of the normal centrosome and/or if the shape of its centro-
some became irregular.
We calculated the percentages of the cells with numerical
centrosome amplification and of the cells with structural cen-
trosome amplification in one case respectively. The percent-
age of the cells with centrosome amplification was determined
by dividing the number of cells with centrosome amplification
by the number of investigated cells. At least 200 cells per slide
were examined. All slides were evaluated without knowing the
diagnosis of cytology and histology.
Cytology diagnosis
For cytological diagnosis, the slides were fixed in 95% alcohol,
were stained by hematoxylin and eosin, and were evaluated by
two cytopathologists in a double-blinded manner. The diag-
noses were categorized into three groups: benign, suspicious
carcinoma, and carcinoma.
Statistical analysis
Patient data including the tumor size, the histological category
and grades, the lymph-nodal status, the estrogen receptor
(ER) status, the progesterone receptor (PR) status, the Her2
status, and DNA ploidy were obtained from the patients' files.
The final histology results were used as the golden standard.
Correlations of centrosome amplification with histological
diagnosis and pathologic prognostic variables (tumor size, his-
tological grades, lymph-nodal status, ER status, PR status,
Her2 status, and DNA ploidy) in breast carcinomas were
assessed via a t test for quantitative data and via the Mann–
Whitney U test or the chi-square test for qualitative data. P <
0.05 was considered statistically significant. All statistics were
calculated with the aid of SPSS, version 12.0 (SPSS, Chi-
cago, IL, USA).
Results
In total, 100 FNAs of breast lesions were included in our study,
including 25 cases of benign lesions, two cases of ductal car-
cinoma in situ and 73 cases of invasive carcinomas character-
ized by their centrosomal status. The benign lesions consisted
of 15 fibroadenomas, five mastopathias, two introductal papil-
lomas, one case of fibrocystic mastopathy, one case of masti-
tis and one case of fatty necrosis. The invasive carcinomas
included 72 cases of invasive ductal carcinomas and one case
of invasive lobular carcinoma (Table 1).
Centrosome expression
Most tumor cells showed normal γ-tubulin staining of the cen-
trosome, with one or two rounded spots of uniform size andAvailable online http://breast-cancer-research.com/content/9/4/R48
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shape located close to the nucleus, but also a few spots near
the cell membrane (Figure 1). A total of 7.3% of cells showed
centrosome amplification with number changes or structural
changes (Figure 2). The observed numerical centrosome
amplification ranged from three to eight per cell, but most were
three per cell. The structural centrosome amplification showed
an enlarged centrosome (diameter of the centrosome greater
than twice the diameter of the centrosome of normal control
cells) with altered shape. String-like, V-shaped and sand-like
irregular shapes were noted in some cells. Interestingly, in the
present study we did not find any one cell that contained both
numerical centrosome amplification and structural centrosome
amplification.
Cells with numerical centrosome amplification were detected
in all cases (75/75) of malignant lesions and in 92% (23/25)
of cases of benign lesions. Cells with structural centrosome
amplification were detected in 92% (69/75) of cases of breast
carcinomas (two cases with ductal carcinoma in situ and 67
cases with invasive carcinoma), and in 12% (3/25) of cases of
benign lesions (one case with mastopathias, one case with
intraductal papilloma and one case with fibrocystic
mastopathy).
Breast carcinomas showed a mean percentage of the cells
with numerical centrosome amplification of 4.86%, and a
mean percentage of cells with structural centrosome amplifi-
cation of 3.98% (Figure 3). These percentages were signifi-
cantly higher than those in benign lesions, which presented a
mean percentage of cells with numerical centrosome amplifi-
cation of 2.77% (P = 0.000) and a mean percentage of cells
with structural centrosome amplification of 0.1% (P = 0.000)
(Table 2).
Cytology diagnosis and centrosome amplification
There were 91 cases that showed exact diagnostic correlation
between cytology diagnoses and histology diagnoses. The
other nine cases were diagnosed as suspicious carcinoma by
cytology. Among these suspicious carcinomas, seven cases
were diagnosed as invasive carcinomas and two cases were
diagnosed as fibroadenomas by histology. All nine suspicious
cases had cells with numerical centrosome amplification. Of
them, six cases of invasive carcinoma also had cells with struc-
tural centrosome amplification; however, the structural
centrosome amplification was not found in the cells of either of
the two cases of fibroadenoma.
Association between centrosome amplification and 
prognostic variables
The correlations of the centrosome amplification levels with
established or proposed prognostic variables of breast carci-
noma were analyzed. The mean percentage of cells with struc-
tural centrosome amplification was significantly associated
with HER2/neu overexpression (P = 0.005) and with ER-neg-
ative status (P = 0.003). There was a borderline significant
Table 1
Patient age and histology diagnosis
Age (years)
Benign tumor 33 (20–50)








Ductal carcinoma in situ 2
Invasive ductal carcinoma 72
Invasive lobular carcinoma 1
Data presented as the mean (range) or as n.
Figure 1
Normal centrosome staining of benign tumors Normal centrosome staining of benign tumors. (a) Fibroadenomas and (b) mastopathias show one or two rounded spots in uniform size and shape. 
(b) Also shows centrosomes near the cell membrane.Breast Cancer Research    Vol 9 No 4    Guo et al.
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association between the mean percentage of cells with struc-
tural centrosome amplification and negative PR status (P =
0.056). The mean percentage of cells with numerical centro-
some amplification was significantly associated with positive
ER status (P = 0.03) and with positive PR status (P = 0.02).
There were no relationships between centrosome amplifica-
tion levels and other prognostic variables (Table 3).
Discussion
The present study performed centrosomal analysis using
slides prepared by the ThinPrep Processor. To our knowledge,
this is the first report that demonstrates the feasibility of cen-
trosomal analysis on ThinPrep slides. Compared with the con-
ventional slides, ThinPrep slides have a cleaner background
and a more distinct cell border than conventional smears
[9,10]. These features are helpful for centrosome examination.
Centrosome amplifications are found in the vast majority of
human malignancies, but whether benign lesions also contain
centrosome defects is still controversial. Pihan and colleagues
[11] and Kronenwett and colleagues [12] found no centro-
some amplification in variant normal epithelia including the
breast, the prostate, the lung, the brain, the colon, and benign
breast lesions. In contrast, Sato and colleagues [7] and
Schneeweiss and colleagues [13] demonstrated centrosome
amplifications in pancreatic adenomas, normal breast tissues
and benign breast lesions. Studies in cell lines also showed
that some noncancer cells contained extra centrosomes
Figure 2
Centrosome amplifications Centrosome amplifications. (a)–(g) Centrosomes with numerical amplification: (a), (d), (f) from fibroadenoma, (b) and (e) from carcinoma, and (c) 
and (g) from mastopathias. (h)–(m) Centrosomes with structural amplifications (all cells come from carcinomas): (h) enlarged centrosome, (i) string-
like centrosome, (j) V-shaped centrosome, (k) sand-like centrosome, and (l) and (m) irregular shape centrosomes.
Figure 3
Centrosome staining of malignant tumors Centrosome staining of malignant tumors. Both (a) ductal carcinoma in situ and (b) invasive carcinoma show centrosome amplifications.Available online http://breast-cancer-research.com/content/9/4/R48
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[14,15]. These cell types can apparently suppress multipolar-
ity and form a pseudo-bipolar spindle during mitosis even
though the centrosomes are amplified. Quintyne and col-
leagues [15] believed that clustering may be an important
mechanism for preserving genomic stability in noncancer
cells.
In our study, centrosome amplification – mostly numerical
amplification – was found in both breast carcinomas and
benign lesions. The structure of and the levels of centrosome
amplification, however, were significantly different between
the carcinomas and benign lesions. First, while cells with
numerical centrosome amplification were found in both benign
and malignant breast lesions, cells with structural centrosome
amplification were mainly found in breast carcinomas: 92% of
cases with breast carcinoma had cells with structural centro-
some amplification, while only 12% of cases with benign
lesions had cells with structural centrosome amplification.
Second, the percentage of cells with numerical centrosome
amplification in breast carcinomas was significantly higher
than that in benign lesions. Breast carcinomas showed mean
percentages of cells with numerical centrosome amplification
and with structural centrosome amplification of 4.86% and
3.98%, respectively, but the mean percentages of cells with
numerical centrosome amplification and with structural centro-
some amplification in benign lesions were 2.77% and 0.10%
(P = 0.000), respectively. These findings suggest that struc-
tural centrosome amplification may have a more close associ-
ation with breast carcinoma. The structural centrosome
amplification observed in our study, including area enlarge-
ment and shape alteration, was accompanied by an increase
of the γ-tubulin immunostaining volume of the centrosome.
These observations suggest that centrosomes with structural
amplification may contain high levels of γ-tubulin proteins. The
γ-tubulin-containing complexes are the site of microtubule
nucleation, which is the key to centrosome function [16]. The
increase of γ-tubulin protein may therefore be critical for cen-
trosome function. Lingle and Salisbury [17] showed that
breast carcinomas with extrapericentriolar material are more
highly anaplastic than carcinomas with supernumerary centro-
somes. They believed that high levels of γ-tubulin proteins in
the pericentriolar material are the main cause of anaplasia.
While the structural centrosome amplification is closely
related to malignance, we analyzed whether it may be an
adjunct marker for FNA cytological diagnoses of breast
lesions. In our study there were nine cases with cytological
diagnosis of suspicious carcinoma, of which seven cases
were diagnosed as invasive ductal carcinoma and two cases
were diagnosed as fibroadenoma by histology. Of the seven
cases with invasive ductal carcinoma, six cases had cells with
structural centrosome amplification. Of the two cases of
fibroadenoma, however, neither had cells with structural cen-
trosome amplification. Centrosome detection may therefore
be used as an auxiliary diagnosis for FNA cytological diag-
noses. While these findings may suggest that structural cen-
trosome amplification may be a marker, more definitive
analysis with larger sample sizes will be needed.
In accordance with findings from other authors [18,19], we
also detected cells with structural centrosome amplification in
ductal carcinoma in situ, suggesting structural centrosome
amplification may be an early event in the process of breast
carcinogenesis.
Centrosome amplification is not only characteristic of tumors
in general, but also is more pronounced in advanced-stage
malignances, in recurrent tumors, and in cell lines that show
more aggressive malignant phenotypes in xenograph animal
models [6,20-22]. These observations suggest that centro-
some amplification might be a useful marker in monitoring
tumor progression. Our results demonstrated a significant cor-
relation of the mean percentage of cells with structural centro-
some amplification with HER2/neu overexpression (P < 0.05)
and with negative ER status (P < 0.05), and demonstrated a
borderline significant association between the mean percent-
age of cells with structural centrosome amplification and neg-
ative PR status (P = 0.056) in breast carcinomas. The mean
percentage of cells with structural centrosome amplification
probably predicates a more aggressive course of breast carci-
noma. In line with our observation, Schneeweiss and col-
leagues [13] found a highly significant correlation of maximum
centrosomal aberration levels with axillary nodal tumor involve-
ment and the absence of hormone receptors in breast carcino-
mas. The mean percentage of cells with numerical centrosome
Table 2
Comparison of the differences in centrosome amplification between benign breast lesions and breast carcinomas
Cases with numerical 
centrosome amplification
Cases with structural 
centrosome amplification
Cells with numerical 
centrosome amplification 
(%)
Cells with structural 
centrosome amplification 
(%)
Benign tumor 23 (92) 3 (12) 2.77 ± 2.14 (2.40) 0.10 ± 0.29 (0.00)
Malignant tumor 75 (100) 69 (92) 4.86 ± 2.66 (4.50) 3.98 ± 3.21 (3.60)
P value 0.10 0.00 0.00 0.00a
Data presented as n (%) or mean ± standard deviation (median). aOwing to a skewed distribution, the Mann–Whitney U-test was applied.Breast Cancer Research    Vol 9 No 4    Guo et al.
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amplification was significantly associated with positive ER sta-
tus (P < 0.05) and with positive PR status (P < 0.05) in breast
carcinomas. No relationship between numerical centrosome
amplification with other prognostic factors of breast carci-
noma was found. Additional prospective studies are again
needed to confirm the observation.
In summary, the present results demonstrate that centrosome
amplification including numerical amplification and structural
amplification is present in breast tumors. Structural centro-
some amplification has close associations with breast carci-
noma and might serve as an adjunct marker in FNA diagnostic
and prognostic evaluations of breast lesions.
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